Biodesix Inc (BDSX) Stock Forecast & Price Target

Biodesix is supported by strong fundamental momentum, with 2Q26 revenue rising 34.2% YoY to $26.9M, Diagnostic Testing up 41.6% on 20,900 tests and improved payor coverage, while gross margin reached 82% and the adjusted EBITDA loss narrowed 56% to $3.2M. The company’s rebuilding sales force, rebound in new-physician acquisition, and faster adoption of Nodify CDT in smaller nodules suggest a more durable volume-growth path, especially as primary-care volume increased 133% but still represented only about 15% of total testing. Its long-term growth case is further strengthened by a two-pronged MRD strategy and scalable health-system implementations that could expand account penetration, repeat utilization, and broader partner-platform deployment.

Biodesix is facing a weak fundamental setup as 3Q26 revenue of $24.0M fell short of the $27.1M expectation despite 10.4% growth, while the company also cut FY2026 revenue guidance to $101M–$103M from $108M–$114M. Diagnostic Tests rose 16.2% to $23.1M on 24% higher volume to 19,400, but a 6% decline in average revenue per test and a CDT-heavy mix signal pricing pressure and less favorable product economics. With an $8.0M net loss, $30.0M in cash versus $50.0M in debt at the end of June 2026, and negative operating cash flow in 2Q26, the business appears under strain and may need additional capital, heightening dilution risk.